Last 32 quarters of trend data · Healthcare · Biotechnology
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -29.27 | — | — | — | 5.11 | — | — | — | — | — | — | — | — | — | — | — | 59.68 | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | 15.05 | 96.85 | 112.63 | 70.39 | 2.94 | — | — | 80.17 | — | — | — | 147.94 | 50.35 | 93.25 | 21.07 | 54.36 | 5.16 | 22.80 | 9.50 | 76.79 | 26.81 |
| — | — | — | -12.2% | — | — | — | -45.8% | — | — | — | +172.1% | +875.1% | +309.1% | +121.7% | -29.2% | -80.7% | +15.8% | -63.1% | +695.7% | +169.7% | |
| P/B Ratio | 3.24 | 2.86 | 3.15 | 2.99 | 2.23 | 1.94 | 1.41 | 2.12 | 2.31 | 2.94 | 3.52 | 3.74 | 3.19 | 2.64 | 1.99 | 2.50 | 1.66 | 1.98 | 1.50 | 3.02 | 3.03 |
| — | +47.7% | +123.1% | +41.3% | -3.4% | -34.0% | -59.9% | -43.3% | -27.4% | +11.5% | +77.1% | +49.4% | +91.6% | +33.0% | +33.0% | -17.1% | -45.1% | -31.0% | -53.3% | +46.7% | +66.1% | |
| P/FCF | — | — | — | — | 4.29 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | — | — | — | 4.95 | — | — | — | — | — | — | — | — | — | — | — | 81.28 | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | — | — | — | 5.00 | — | — | — | — | — | — | — | — | — | — | — | 79.77 | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 97.9% | 100.0% | -1359.2% | -696.2% | 100.0% | — | — | 90.8% | — | — | — | 73.9% | 87.7% | 71.8% | 87.8% | 86.1% | 96.9% | 79.4% | 95.9% | 85.7% | -72.7% |
| — | — | — | -866.7% | — | — | — | +22.9% | — | — | — | -14.2% | -9.4% | -9.5% | -8.4% | +0.5% | +233.2% | +211.8% | +260.9% | -11.3% | -175.1% | |
| Operating Margin | -72.8% | -1380.7% | -1654.6% | -869.5% | 52.2% | — | — | -2059.1% | — | — | — | -1068.5% | -417.1% | -922.9% | -333.5% | -657.5% | 2.2% | -384.5% | -125.2% | -619.9% | -130.5% |
| — | — | — | +57.8% | — | — | — | -92.7% | — | — | — | -62.5% | -18868.6% | -140.0% | -166.4% | -6.1% | +101.7% | -204.7% | +0.7% | -1141.2% | -134.2% | |
| Net Margin | -52.0% | -1269.6% | -1502.1% | -765.7% | 57.4% | — | — | -1861.6% | — | — | — | -865.5% | -341.4% | -788.0% | -300.0% | -601.7% | 5.4% | -377.0% | -123.4% | -614.6% | -129.0% |
| — | — | — | +58.9% | — | — | — | -115.1% | — | — | — | -43.8% | -6377.8% | -109.0% | -143.2% | +2.1% | +104.2% | -201.5% | +0.9% | -1165.3% | -134.9% |
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -10.9% | -10.5% | -10.1% | -7.9% | 11.6% | -7.8% | -6.9% | -11.6% | -4.9% | -5.7% | -5.1% | -6.0% | -5.4% | -6.7% | -6.9% | -6.7% | 0.5% | -7.9% | -4.7% | -5.9% | -4.2% |
| — | -34.8% | -46.7% | +32.3% | +336.9% | -38.2% | -34.8% | -93.5% | +9.7% | +15.4% | +26.5% | +10.8% | -1173.8% | +15.4% | -45.7% | -14.6% | +112.2% | -70.9% | -13.5% | -125.5% | -54.9% | |
| ROA | -10.2% | -9.6% | -9.2% | -7.3% | 10.7% | -7.2% | -6.4% | -11.0% | -4.7% | -5.5% | -4.9% | -5.7% | -5.2% | -6.3% | -6.3% | -6.1% | 0.4% | -6.3% | -3.8% | -4.7% | -3.2% |
| — | -32.8% | -43.5% | +34.2% | +328.8% | -32.7% | -30.7% | -91.9% | +9.5% | +12.9% | +21.8% | +5.2% | -1299.8% | +1.1% | -65.9% | -29.9% | +113.6% | -89.2% | -31.0% | -172.4% | -57.0% | |
| ROIC | -12.4% | -10.4% | -9.2% | -7.9% | 9.6% | -7.4% | -6.6% | -12.1% | -6.5% | -6.2% | -5.9% | -7.6% | -6.6% | -7.3% | -7.1% | -7.1% | 0.2% | -7.3% | -4.7% | -6.4% | -4.7% |
| — | -39.9% | -38.8% | +34.1% | +248.5% | -20.6% | -12.0% | -58.3% | +2.2% | +15.7% | +17.0% | -6.6% | -3411.8% | -0.3% | -51.1% | -11.4% | +104.2% | -13.8% | +19.0% | -106.0% | +3.8% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.03 | 0.02 | 0.03 | 0.05 | 0.02 | 0.03 | 0.03 | 0.02 | 0.02 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.01 | 0.01 | 0.01 | 0.02 | 0.02 | 0.02 | 0.02 |
| — | -11.8% | +20.3% | +199.7% | +56.7% | +1281.6% | +885.5% | +291.4% | +285.7% | -60.9% | -71.7% | -53.6% | -61.2% | -68.3% | -45.1% | -42.0% | -39.5% | -35.0% | -39.3% | -49.3% | -51.5% | |
| Debt / EBITDA | — | — | — | — | 0.25 | — | — | — | — | — | — | — | — | — | — | — | 2.48 | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 11.34 | 10.45 | 10.74 | 11.34 | 12.44 | 12.39 | 13.92 | 14.97 | 22.93 | 17.50 | 28.42 | 19.65 | 19.37 | 19.80 | 11.53 | 11.68 | 12.02 | 4.69 | 4.50 | 5.56 | 6.96 |
| — | -15.6% | -22.9% | -24.3% | -45.7% | -29.2% | -51.0% | -23.8% | +18.4% | -11.6% | +146.4% | +68.3% | +61.1% | +322.7% | +156.6% | +110.1% | +72.7% | -40.1% | -47.3% | -25.6% | +34.0% | |
| Quick Ratio | 11.34 | 10.45 | 10.74 | 11.34 | 12.44 | 12.39 | 13.92 | 14.97 | 22.93 | 17.50 | 28.42 | 19.65 | 19.37 | 19.80 | 11.53 | 11.68 | 12.02 | 4.69 | 4.50 | 5.56 | 6.96 |
| — | -15.6% | -22.9% | -24.3% | -45.7% | -29.2% | -51.0% | -23.8% | +18.4% | -11.6% | +146.4% | +68.3% | +61.1% | +322.7% | +156.6% | +110.1% | +72.7% | -40.1% | -47.3% | -25.6% | +34.0% | |
| Interest Coverage | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 32 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying IDYA stock.
IDEAYA Biosciences, Inc.'s current P/E is -29.3x. The average P/E over the last 1 quarters is 5.1x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
IDEAYA Biosciences, Inc.'s current operating margin is -72.8%. Margins have been compressing over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking IDEAYA Biosciences, Inc.'s business trajectory between earnings reports.